Medical Weight Loss Treatment for Vermont Residents
Medically Supervised Weight Loss, Delivered Online
Our providers are licensed by the Vermont Board of Medical Practice to deliver telehealth throughout the Green Mountain State.
Whether you're in Burlington, Montpelier, or anywhere across Vermont — our board-certified providers are ready to see you.
Medical Weight Loss Treatment in Vermont
Our board-certified providers prescribe FDA-approved and physician-developed weight loss medications including GLP-1 agonists, customized to your health profile and goals.
No office visits required — 100% online consultations
FDA-approved and physician-developed medications
Personalized dosing protocols adjusted to your response
Ongoing provider support and check-ins throughout treatment
Medications shipped directly to your door from licensed pharmacies
Vermont's Green Mountains and pastoral landscapes attract people seeking a simpler life—but healthcare access shouldn't be complicated. OmniRx Health serves the entire state, from Burlington's lakeside community to the ski towns of Stowe and Killington, the college town of Middlebury to the Northeast Kingdom's remote beauty. Our telehealth platform brings expert care to every town and village, eliminating the need to navigate mountain roads for medical appointments.
Available Treatments in Vermont
Our board-certified providers in Vermont can prescribe and manage the following treatment options
Semaglutide
Semaglutide is a GLP-1 receptor agonist that reduces appetite and slows gastric emptying, helping patients achieve significant, sustained weight loss. Originally developed for type 2 diabetes management, semaglutide has become one of the most clinically effective weight loss medications available.
Tirzepatide
Tirzepatide is a dual GLP-1 and GIP receptor agonist that produces even greater weight loss than semaglutide alone. It addresses appetite, blood sugar regulation, and metabolic rate through two complementary hormonal pathways for superior outcomes.
Tesofensine
Tesofensine is a triple monoamine reuptake inhibitor that suppresses appetite and boosts metabolism through dopamine, norepinephrine, and serotonin pathways. Originally developed as an anti-Parkinson's agent, it showed exceptional weight loss properties in clinical trials.
Retatrutide
Retatrutide (LY3437943) is a 39-amino acid synthetic peptide and triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program), it produced 24.2% average weight loss at 48 weeks in Phase 2 data — the highest weight reduction observed in any peptide trial to date. Listed by OmniRx for research-use only (RUO).
Telehealth Regulations in Vermont
State Licensing
Our providers are licensed by the Vermont Board of Medical Practice to deliver telehealth throughout the Green Mountain State.
Telehealth Law
Vermont has comprehensive telehealth laws that support virtual care while addressing the unique needs of its rural population.
Pharmacy Access
Vermont pharmacies in Burlington, Montpelier, and throughout rural communities provide prescription services with statewide delivery.
Insurance Notes
Vermont requires telehealth coverage parity, ensuring virtual visits are covered like in-person appointments.
Frequently Asked Questions
Common questions about medical weight loss and telehealth access in Vermont
Explore Related Medical Weight Loss Pages
Direct links to specific treatments and other states.